vaayaa Inclusive Education
Healthcare risk assessment

Dermatology and Aesthetic Medicine Risk Assessment: Procedure Safety, Infection, Consent and Privacy Controls

A worked example of how a dermatology and aesthetic clinic finds, scores and controls the risks to patient safety, infection control, consent, records, product supply and staff competence that arise in consultations and minor procedures.

Updated November 2026 8 hazards assessed Review every 3 months Highest risk: High to Medium
See the Dermatology and Aesthetic Medicine course

Executive summary

This assessment shows how a dermatology and aesthetic medicine clinic can find, rate and control the risks that matter most to patient safety, trust and continuity of care. Eight hazards were chosen because they are plausible in everyday consultations, minor procedures, light and laser treatments and injectable work. Procedure complications, infection and equipment faults are the most likely to cause direct harm, while consent gaps, privacy breaches and unrealistic promotion carry serious legal and reputational weight. Each hazard is scored before controls and again after existing and additional controls. Most residual scores fall to Medium or Low once controls are in place, but procedure complication and infection remain Medium because the impact of harm stays serious. The first actions are a structured pre-treatment checklist, a decontamination audit, a consent and photograph policy, and a tested recovery plan for records. Specialist clinical, legal and regulatory review is needed for any real decision.

Focus area
Dermatology and aesthetic medicine
Setting
Outpatient dermatology and aesthetic clinic offering consultations, minor skin procedures, light and laser treatments and injectable treatments
Method
Five by five likelihood and impact clinical risk register

Scope

This assessment covers a teaching clinic that offers dermatology consultations, minor skin procedures, laser and light treatments and aesthetic injectables. It covers patient safety, infection control, equipment, consent, records, privacy, staff competence and service continuity. It does not cover surgery under general anesthesia, detailed pharmacy supply chains or any real clinic. Jurisdiction, licensing, staffing levels and equipment models are assumptions made for teaching and must be confirmed locally with specialist review.

Context

The clinic has two dermatologists, a nurse prescriber, two trained aestheticians and a receptionist. Consultations and treatments are recorded in an electronic record system, with clinical photographs stored in a separate image store. Lasers, light devices and reusable instruments are shared between treatment rooms. Products are bought from a limited number of approved suppliers and kept in a locked store. Each hazard is scored before controls to show its natural level, then again after the existing controls and the additional controls that should be added. Scores are illustrative and do not describe a real service.

Objectives, assets and stakeholders

The objective is to deliver safe, effective and honest care, protect patients from harm, keep records accurate and private, and maintain trust with patients, referrers and regulators. The assets in scope are patients and their wellbeing, clinical photographs and records, medicines and aesthetic products, laser and light equipment, reusable instruments, the clinic premises and the professional reputation of the team. Stakeholders include patients and their families, clinicians, nurses, aestheticians and reception staff, the responsible clinical lead, equipment and product suppliers, referring doctors, the information governance lead and regulators. Clear roles matter. Each hazard has one owner role, and the clinical lead reports the register to the clinic governance meeting each quarter.

Risk matrix: before and after controls

Each cell shows hazard numbers placed by likelihood and impact. Compare the two grids to see how controls move each hazard.

Before controls

Inherent risk

Risk before controls: rows are likelihood from almost certain to rare, columns are impact from insignificant to catastrophic. Cells list hazard numbers.
1
Insignificant
2
Minor
3
Moderate
4
Major
5
Catastrophic
5 Almost certain
4 Likely Likelihood 4, impact 3, score 12, high: H05 Likelihood 4, impact 4, score 16, high: H01
3 Possible Likelihood 3, impact 3, score 9, medium: H08 Likelihood 3, impact 4, score 12, high: H03 H06 H07 Likelihood 3, impact 5, score 15, high: H02
2 Unlikely Likelihood 2, impact 5, score 10, high: H04
1 Rare

After controls

Residual risk

Risk after controls: rows are likelihood from almost certain to rare, columns are impact from insignificant to catastrophic. Cells list hazard numbers.
1
Insignificant
2
Minor
3
Moderate
4
Major
5
Catastrophic
5 Almost certain
4 Likely
3 Possible
2 Unlikely Likelihood 2, impact 2, score 4, low: H08 Likelihood 2, impact 3, score 6, medium: H03 H05 H06 H07 Likelihood 2, impact 4, score 8, medium: H01 H02 H04
1 Rare
  • Low 1 to 4
  • Medium 5 to 9
  • High 10 to 16
  • Critical 17 to 25

Hazard register

A summary first, then the detail for each hazard.

Summary of hazards with scores before and after controls
No.HazardBeforeAfterOwner
H01 Procedure complication and adverse reaction not recognized early 16 High 8 Medium Lead dermatologist
H02 Infection and cross contamination between patients 15 High 8 Medium Infection control lead
H03 Equipment malfunction or unsafe laser and light use 12 High 6 Medium Practice manager
H04 Unregistered, counterfeit or degraded product supply 10 High 8 Medium Pharmacy or product lead
H05 Consent and documentation gaps 12 High 6 Medium Lead dermatologist
H06 Privacy breach of clinical images and records 12 High 6 Medium Information governance lead
H07 Competence gaps and unsupervised delegation 12 High 6 Medium Clinical lead
H08 Unrealistic expectations and misleading promotion 9 Medium 4 Low Practice manager
H01

Procedure complication and adverse reaction not recognized early

Safety Before 16 After 8

Injectable, laser or peel treatments cause bruising, burns, vascular compromise, allergic reaction or infection, and warning signs are missed because the pre-treatment assessment is brief or aftercare is not explained.

Who or what is affected: Patients, clinicians and reception staff who handle urgent calls

Causes

Brief pre-treatment assessment, incomplete medicine history and pressure to fit treatments into a busy appointment list.

Consequences

Avoidable harm, delayed treatment, complaints and the need for emergency transfer.

Existing controls

  • A clinician reviews each patient before any procedure starts.
  • Patients receive written aftercare advice when they leave the clinic.

Control gaps

Aftercare is not followed up by phone, so early complications may not be reported until they are severe.

Additional controls

  • Prevent: Use a structured pre-treatment checklist with contraindications, allergies and medicines reviewed and signed.
  • Respond: Keep an emergency kit and a rehearsed plan for anaphylaxis, vascular compromise and burns, checked each month.
Likelihood 4 x impact 4 before; 2 x 4 after Owner: Lead dermatologist Target: Within 30 days Early warning: Patients who return unplanned for a complication within 14 days of a procedure.
H02

Infection and cross contamination between patients

Safety Before 15 After 8

Reusable instruments, multi-dose vials, gel and laser handpieces are shared or not decontaminated correctly, allowing bacterial or viral transfer between patients and to staff.

Who or what is affected: Patients, staff and visitors who share the treatment rooms

Causes

Multi-dose vials reused between patients, rushed cleaning between appointments and unclear labeling of single-use items.

Consequences

Patient infection, an outbreak within the clinic, regulator enquiry and loss of patient trust.

Existing controls

  • Single-use needles and syringes are used for each patient.
  • Reusable instruments are cleaned and sterilized in a separate room.

Control gaps

Room surfaces are cleaned by different staff with no shared checklist, so cleaning standards vary.

Additional controls

  • Prevent: Audit each decontamination cycle and label instruments with the date and cycle result before storage.
  • Detect: Review sterilizer logs and cleaning checks each month and record any failed cycle with the action taken.
Likelihood 3 x impact 5 before; 2 x 4 after Owner: Infection control lead Target: Within 30 days Early warning: A missed or incomplete decontamination check found in the monthly audit.
H03

Equipment malfunction or unsafe laser and light use

Safety Before 12 After 6

Lasers, intense pulsed light devices and radiofrequency units are used with wrong settings, without eye protection or after a fault, causing burns, eye injury, scarring or pigment change.

Who or what is affected: Patients, clinicians and anyone present in the treatment room

Causes

Shared devices, settings copied from memory and service records that are not kept up to date.

Consequences

Burns, scarring, eye injury, pigment change and claims against the clinic.

Existing controls

  • Operators complete device training before using any laser or light device.
  • Protective eyewear is worn for all light-based treatments.

Control gaps

Service dates are kept on paper and are not checked against the device use log.

Additional controls

  • Prevent: Set and record energy, pulse and skin type for each treatment on a standard form.
  • Respond: Stop the device on any fault, label it out of service and report the fault to the supplier and the responsible person.
Likelihood 3 x impact 4 before; 2 x 3 after Owner: Practice manager Target: Within 60 days Early warning: A device used beyond its service interval or without a current calibration record.
H04

Unregistered, counterfeit or degraded product supply

Supplier Before 10 After 8

Botulinum toxin, dermal fillers, topical agents or skin care products are bought from unverified sources, stored poorly or mislabeled, so the product may be counterfeit, degraded or unsuitable for use.

Who or what is affected: Patients receiving treatment and staff who handle the products

Causes

Price pressure, demand to offer treatments quickly and unclear checks on supplier status.

Consequences

Adverse reactions, treatment failure, legal liability and reputational damage.

Existing controls

  • Purchases are made only from named suppliers on a written approved list.
  • Stock is kept in a locked store with logged temperature checks.

Control gaps

Batch numbers are not always recorded against the patient record, so affected patients are hard to trace.

Additional controls

  • Prevent: Verify supplier registration and batch details before accepting any delivery into stock.
  • Respond: Quarantine suspect batches, record the batch numbers used and inform affected patients through the clinical lead.
Likelihood 2 x impact 5 before; 2 x 4 after Owner: Pharmacy or product lead Target: Within 45 days Early warning: A product batch received without a traceable label or verified supplier registration.
H05

Consent and documentation gaps

Legal and compliance Before 12 After 6

Consent is taken without a clear explanation of risks, alternatives, costs and expected outcomes, or records are incomplete, so the clinic cannot show what was agreed, done and checked afterwards.

Who or what is affected: Patients, clinicians and the clinic in any dispute or investigation

Causes

Rushed consultations, generic forms and patients who do not read the information before treatment.

Consequences

Complaints, professional investigation, weak defense in a claim and loss of trust.

Existing controls

  • A signed consent form is kept for each procedure.
  • Clinicians record the main points of each consultation in the record.

Control gaps

Aftercare and photograph consent are recorded separately and are not always linked to the treatment record.

Additional controls

  • Prevent: Use a standard consent discussion covering risks, alternatives, costs and outcomes, with time for questions.
  • Detect: Audit a monthly sample of records for signatures, dated notes and product batch entries.
Likelihood 4 x impact 3 before; 2 x 3 after Owner: Lead dermatologist Target: Within 45 days Early warning: Consent forms missing, unsigned or undated in the monthly audit sample.
H06

Privacy breach of clinical images and records

Technology and data Before 12 After 6

Clinical photographs, records and messages are shared on personal phones, sent through unsecured email or left open on shared screens, exposing sensitive health and body image information.

Who or what is affected: Patients, staff and anyone identifiable in the images or records

Causes

Personal devices used for convenience, unclear rules on using images for marketing and screens left open in reception.

Consequences

Distress to patients, regulator attention, legal claims and loss of professional trust.

Existing controls

  • Records are kept in a password protected system with individual logins.
  • Staff are reminded not to share patient images on social media.

Control gaps

Access rights are not reviewed when staff change roles or leave the clinic.

Additional controls

  • Prevent: Store clinical photographs only in the approved image system, with access limited to the treating team and written permission for each use.
  • Recover: Rehearse notifying affected patients and restoring records from a tested backup.
Likelihood 3 x impact 4 before; 2 x 3 after Owner: Information governance lead Target: Within 30 days Early warning: Clinical images found on personal devices or in unapproved messaging during an audit.
H07

Competence gaps and unsupervised delegation

People Before 12 After 6

Staff perform treatments beyond their training or supervise colleagues they have not been assessed to supervise, so decisions are made without the skill or authority needed.

Who or what is affected: Patients, junior staff and supervising clinicians

Causes

Demand pressure, unclear boundaries between roles and training that is not refreshed.

Consequences

Avoidable harm, professional conduct concerns and suspension of practice rights.

Existing controls

  • Each member of staff has a written scope of practice signed by the clinical lead.
  • Clinical staff complete an annual competence assessment.

Control gaps

Scopes of practice are not updated when new treatments are added to the service.

Additional controls

  • Prevent: Check each booked treatment against the scope of practice of the named staff member before the appointment.
  • Detect: Review a sample of treatments each quarter for supervision and sign off against the scope of practice.
Likelihood 3 x impact 4 before; 2 x 3 after Owner: Clinical lead Target: Within 60 days Early warning: A treatment booked with a staff member who does not hold the matching scope of practice.
H08

Unrealistic expectations and misleading promotion

Reputational Before 9 After 4

Marketing claims, before and after images or social media offers promise results that are unlikely, pressure patients into treatment, or hide risks and costs, which can cause distress and complaints.

Who or what is affected: Patients, prospective patients and the clinic team

Causes

Competitive pressure, social media trends and promotional targets for treatment numbers.

Consequences

Complaints, regulator scrutiny, refunds and reputational harm to the clinic.

Existing controls

  • A clinician reviews promotional material before it is published.
  • Patients receive a written summary of expected outcomes and risks.

Control gaps

Posts made by staff on personal accounts are not checked before they are shared.

Additional controls

  • Prevent: Publish only results with a clear statement of typical outcome, risk and the need for a consultation.
  • Respond: Withdraw any promotion that overstates results and inform the clinical lead the same day.
Likelihood 3 x impact 3 before; 2 x 2 after Owner: Practice manager Target: Within 30 days Early warning: A complaint or enquiry that quotes a promised result or a discounted price offer.

Rating method and evaluation

Each hazard is rated on two five-point scales. Likelihood runs from 1 for Rare to 5 for Almost certain, and impact runs from 1 for Minimal to 5 for Severe harm or loss. Multiplying the two gives a score from 1 to 25, which falls into one of four bands: Low from 1 to 4, Medium from 5 to 9, High from 10 to 16 and Critical from 17 to 25. The score is a guide for ordering work, not a precise measurement. Inherent risk is the score before any controls, judged as if the existing controls were absent. Residual risk is the score after the existing and additional controls are in place. Residual score must never be higher than inherent, and where inherent is 10 or more, residual must be lower. Impact is judged on physical harm to patients, distress, time to correct, legal exposure and damage to trust. Any risk that stays High needs senior clinical attention and a dated plan. Medium risks need routine controls with a named owner. Low risks are accepted and watched. Ratings are challenged by the clinicians who do the work, by peer review at each governance meeting and by any incident that does not match its score. Ratings are also reviewed whenever a warning indicator reaches its threshold, and specialist review is needed before a rating is used for any clinical decision.

Likelihood, impact and rating bands

Likelihood

  • 5 Almost certain: Expected to happen in most circumstances.
  • 4 Likely: Will probably happen in many circumstances.
  • 3 Possible: Could happen at some time.
  • 2 Unlikely: Not expected, but it could happen.
  • 1 Rare: Only in exceptional circumstances.

Impact

  • 1 Insignificant: No lasting effect. Handled within routine work.
  • 2 Minor: Small effect that is quickly corrected.
  • 3 Moderate: Noticeable effect that needs managed effort to correct.
  • 4 Major: Serious effect on people, delivery or reputation.
  • 5 Catastrophic: Severe or lasting effect that threatens the whole activity.

Bands (likelihood x impact)

  • Low (1 to 4): Accept and monitor.
  • Medium (5 to 9): Manage with routine controls.
  • High (10 to 16): Senior attention and a treatment plan.
  • Critical (17 to 25): Act first. Do not proceed until reduced.

Monitoring, escalation and review

Review this assessment every 3 months, and sooner when an indicator below reaches its threshold.

Early-warning indicators and escalation thresholds
Indicator to watchEscalate when
Patients who need unplanned review or treatment for a complication within 14 days of a procedure.Escalate to the clinical lead the same day, and to the clinic governance meeting if the count rises in a quarter.
Sterilization or single-use checks that are missed or recorded as incomplete in the monthly audit.Escalate to the infection control lead at once, and stop use of the affected instrument until it is cleared.
Laser or light devices used beyond the service interval or without a current calibration record.Escalate to the practice manager at once, and take the device out of use until its service record is complete.
Consent forms or photograph permissions missing or unsigned in the monthly sample of records.Escalate to the information governance lead when any gap is found, and to the clinical lead if more than one appears in a month.
Product batches received without verified supplier registration or without a traceable label.Escalate to the pharmacy or product lead at once, quarantine the stock and inform the clinical lead the same day.

Contingency arrangements

If a serious adverse event occurs, such as an unexpected reaction, a confirmed infection cluster or a device fault that may have injured a patient, the clinician in charge stops the affected treatment, gives immediate first aid and arranges emergency transfer where needed. The clinical lead informs the patient, records the event and reports it through the local incident route. Affected equipment is locked out and the supplier is contacted. Records are preserved, and the information governance lead is told if data may have been lost or exposed. Regulator and insurer notices are made through the clinical lead as required in the relevant jurisdiction, with specialist legal advice sought.

Prioritized action plan

  1. Introduce a structured pre-treatment checklist with documented clinical assessment and an aftercare plan, owner clinical lead, within 30 days.
  2. Audit sterilization, single-use labeling and room cleaning for every procedure room, owner infection control lead, within 30 days.
  3. Adopt a written consent, photograph and data sharing policy and check it at each consultation, owner information governance lead, within 45 days.
  4. Set up a service and calibration log for lasers and light devices with a named responsible person, owner practice manager, within 60 days.
  5. Confirm that only verified, registered product suppliers are used and that stock is checked on receipt, owner pharmacy or product lead, within 45 days.

Conclusion

Safe aesthetic and dermatology care depends on a few steady habits: structured pre-treatment checks, strict decontamination, written and signed consent, careful records and honest information for patients. The highest inherent scores sit with procedure complications, infection and equipment faults, and each has actions that bring the residual score down. Treat the register as a living record, review it every three months or sooner after an incident, and seek qualified clinical, legal and regulatory advice for any real decision.

Assumptions and limitations

Assumptions

  • Jurisdiction and licensing rules are not specified, so legal duties are described only in general terms.
  • Only clinicians with the required training perform procedures, and the lead dermatologist holds overall clinical responsibility.
  • Equipment is maintained by the manufacturer or a qualified service provider under a written agreement.
  • Patients are adults who attend by appointment and can receive written information in advance.

Limitations

  • The scores are examples for learning and do not describe any real clinic, patient group or regulator decision.
  • Medical, legal and device rules vary by location and change over time, so specialist review is needed.
  • This is educational content and is not clinical, legal or professional advice, and it does not replace a formal site-specific risk assessment.

Related frameworks to study

  • Hierarchy of controls
  • Clinical governance cycle
  • Incident reporting and learning cycle
  • Informed consent principles
  • Infection prevention and control basics

Healthcare Risk Assessment

China, India, United States, Indonesia, Pakistan, Nigeria, Brazil, Bangladesh, Russia, Japan, Mexico, Philippines, Vietnam, Egypt, Turkey, Germany, United Kingdom, France, Italy, Canada, South Korea, Australia, Spain.

For Learning Reference Only: This assessment demonstrates how risk assessment principles are applied in a practical setting, providing a useful reference for learning and understanding. Actual assessments may be adapted to suit specific site conditions and circumstances.

Keep learning

Study the subject behind this assessment.

More Healthcare risk assessments

Hourly Active: 45,552 Learners